Compare AbbVie Inc (ABBV) vs LYFT Inc (LYFT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs LYFT Inc — how do they compare? AbbVie Inc trades at $253.89 (market cap $449.91B), while LYFT Inc trades at $15.03 (market cap $5.86B). The key difference: AbbVie Inc is far larger — about 76.8× LYFT Inc's market cap, and AbbVie Inc pays a 2.72% dividend while LYFT Inc pays none. Which is the better fit depends on your goals.
| ABBV | LYFT | |
|---|---|---|
Market Cap | $449.91B | $5.86B |
Sector | Health | Industrials |
52-Week High | $261.07 | $24.57 |
52-Week Low | $184.85 | $12.65 |
Enterprise Value | $513.38B | $5.40B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Lyft trades at $15.44, up 0.46% today, with a bullish technical signal from moving averages and oscillators. The company shows strong profitability with 43.82% net income margin and robust cash flow generation of $1.17B from operations in 2025. Recent management changes include the appointment of Senthil Padmanabhan as CTO effective July 2026, signaling continued operational focus.
Lyft presents an attractive valuation with P/E of 2.25 and P/S of 0.97, trading below the $18.25 consensus price target. However, mixed earnings performance and competitive pressures from Uber require monitoring. The stock offers upside potential but faces execution risks in the evolving ridesharing market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
